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 Objectives and outline of the questionnaire 
Hereditary breast and ovarian cancer syndrome (HBOC) is a hereditary tumor 
that can be definitively diagnosed by detection of germline mutation of the 
BRCA1 or BRCA2 gene. In other countries, the National Comprehensive 
Cancer Network (NCCN) Clinical Practice Guidelines in Oncology suggest risk-
reducing surgery (risk-reducing mastectomy or risk-reducing salpingo-
oophorectomy (RRSO)) as an option for cancer prevention in cases that have 
been definitively diagnosed with HBOC1). With ovarian cancer in particular, 
preclinical salpingo-oophorectomy is considered to be the most effective 
preventive method, since a method of examination that is effective for early 
detection has yet to be established. This procedure is therefore recommended 
for women of appropriate age, such as those who have finished childbirth. In 
Japan, “Development of communication program regarding genetic counseling 
and testing for breast and ovarian cancer patients” (Research Grant of Ministry 
of Education, Culture, Sports, Science and Technology. 2012.4.1-2015.3.31) 
group carried out a fact-finding survey of HBOC among specialists in 
gynecologic oncology by administering the report as “a survey of the practice 
patterns of gynecologic oncologists dealing with hereditary cancer patients in 
Japan”2). The results of this study showed that a cooperative response to HBOC 
by obstetrician-gynecologists, clinical geneticists, and certified genetic 
counsellors was an urgent issue. In addition, it was found that 9.5% of facilities 
(n=306) are able to carry out RRSO, some of these facilities carry out more 
than 50 procedures a year, and 25% of these facilities carry out this procedure 
as regular medical care. While the survey carried out by this research group 
was aimed at specialists in gynecologic oncology, it was anonymous, and the 
results showed that, with insufficient response to the needs and with no 
treatment systems in place in Japan, there are concerns that inappropriate 
medical care may be given to HBOC patients. Given this situation, the HBOC 
Public Awareness and Management Sub-committee of the Tumor Committee, 
Japan Society of Obstetrics and Gynecology, carried out a fact-finding survey of 
HBOC medical treatment in Japan with the aim of constructing a system for 
appropriate examinations. Specifically, a questionnaire on HBOC medical care 
was given to the core facilities of the Japan Society of Obstetrics and 
 Gynecology, the results of which are presented here. In addition, views 
regarding RRSO for persons with mutations of the BRCA1 or BRCA2 gene 
based on an analysis of the results are shown. 
 
Methods 
The present questionnaire was approved by the Clinical Research Review 
Board of the Japan Society of Obstetrics and Gynecology. The directors of 
medical specialty teaching facilities were notified of the questionnaire by post, 
with the request for one respondent per facility. The questionnaire was 
administered online from the homepage of the Japan Society of Obstetrics and 
Gynecology. The response period was from 8 July 2014 to 31 March 2015. 
The questionnaire items were as follows.  
1. Characteristics of the facility (Questions 1–8) 
2. Treatment system for hereditary diseases (Questions 9–12) 
3. Response to women with a high possibility of HBOC on the basis of prior 
history or family history (Questions 13–15) 
4. Treatment system related to HBOC genetic testing (Questions 16–21) 
5. HBOC counselling system (Questions 22–26) 
6. System for surveillance of ovarian cancer in relation to HBOC (Questions 
27–35)  
7. Present system and future plans regarding risk-reducing salpingo-
oophorectomy (RRSO) for HBOC patients (Questions 36–44) 
8. The primary specialty of clinical geneticists at facilities that have clinical 
geneticists who have been certified by the Japan Society of Human Genetics 
and the Japanese Society for Genetic Counseling (Question 45) 
 
Results 
A total of 341 facilities (50.3%) responded of the 678 that were requested to 
compete the questionnaire. The responses are shown in the respective tables. 
For questions with free responses, similar answers have been grouped together, 
and the written answers have been freely translated. 
 
Views regarding RRSO for women with mutations of BRCA1 and BRCA2  
 Women who have mutations of the BRCA1 or BRCA2 genes (BRCA1/2), which 
are both genes that cause HBOC, have a lifelong, high risk of breast and 
ovarian cancers. The risk of ovarian cancer is reported to be 39–46% in women 
with mutation of the BRCA1 gene and 12–27% in women with mutation of the 
BRCA2 gene. The Japan Society of Obstetrics and Gynecology believes that it 
is essential that the risk of ovarian and/or breast cancer for individuals with 
BRCA1/2 gene mutation is understood, and that appropriate measures are 
taken when obstetrics and gynecology departments make diagnoses. 
Risk assessment, genetic counseling, genetic testing, interpretation of test 
results, and HBOC surveillance (monitoring) are all necessary steps in the 
treatment of hereditary tumors. General obstetrician-gynecologists may be 
assumed to be the main persons involved in risk assessment and HBOC 
management, but when a patient is being treated for HBOC, this should be 
done in collaboration with an expert in clinical genetics who is fully conversant 
with hereditary tumors.  
Studies have shown that 10–15% of patients with ovarian cancer, fallopian 
tube cancer, and primary peritoneal cancer have BRCA1/2 gene mutation. On 
this basis, risk assessment should be carried out with reference to the genetic 
evaluation standards of the NCCN Guidelines, and if the criteria are met, 
consideration should be given to the provision of genetic counseling and to 
presentation of the significance and possibilities raised by BRCA1/2 testing.  
The options available to women with BRCA1/2 gene mutation for prevention 
of ovarian cancer are RRSO and chemoprevention with oral contraceptives as 
primary prevention (to prevent cancer), and strict surveillance, etc. as 
secondary prevention (for early detection and early treatment of cancer). RRSO 
is the most reliable prevention of ovarian cancer for women with BRCA1/2 gene 
mutation at this point. In addition, RRSO not only reduces the risk of ovarian 
cancer onset, it has also been reported to be effective in reducing the initial 
diagnosis of breast cancer and prolonging overall survival. For this reason, 
RRSO is recommended in the guidelines of other countries. 
RRSO involves the ethical issue of removing internal organs that are likely to 
be (phenotypically) healthy. In addition, cooperation with a department that can 
provide pathological diagnosis of occult cancer or the presence of precancerous 
 lesions in the epithelium of the fallopian tubes is needed. The Japan Society of 
Obstetrics and Gynecology therefore considers that the following conditions 
must be met before RRSO is carried out. 
System prior to carrying out RRSO 
1. HBOC genetic counseling must be carried out at a facility that has specialist 
staff. In the cases of a positive test result for BRCA1/2 gene mutation, genetic 
counseling is carried out again, and the client’s autonomy and wishes 
concerning RRSO must be respected. 
2. Sufficient counseling and information provision must be given with regard to 
the efficacy and adverse effects of RRSO, including whether the client wishes to 
have a baby, the cancer risk, and the extent to which RRSO can prevent breast 
cancer and ovarian cancer, as well as possible future health effects such as 
ovarian deficiency symptoms, osteoporosis, and cardiovascular disease, and 
their countermeasures. 
Candidates for RRSO  
3. As a general rule, candidates for RRSO are women with no ovarian cancer 
who are shown to have a pathological BRCA1/2 gene mutation (or a mutation 
that can be determined pathologically and clinically). 
4. The timing of RRSO should depend on the individual, but carrying out the 
procedure after the client has finished childbirth and reached an age of 35–40 
years, or at the earliest age when someone in the client’s family lineage has 
been diagnosed with ovarian cancer, is generally considered desirable. 
Facilities carrying out RRSO 
5. Facilities carrying out RRSO must be reviewed by an ethics committee 
established within the hospital. 
6. Facilities carrying out RRSO must have a system in place for HBOC genetic 
counseling. 
7. To carry out RRSO, a facility must have a full-time specialist of the Japan 
Society of Gynecologic Oncology or be able to create a system of collaboration 
with a specialist. 
8. There must be a system of cooperation in place with pathologists who have a 
full understanding of the handling of biopsy samples. 
 9. Because RRSO results in surgical menopause, there are concerns over 
menopausal symptoms, such as ovarian deficiency symptoms, and negative 
effects on the lipid profile and bone metabolism. For this reason, follow-up by an 
obstetrics and gynecology specialist who is well versed in women’s healthcare 
is needed. Hormone replacement therapy is useful for health promotion 
following RRSO for women with no history of breast cancer, and it is reported to 
have little effect on the risk of breast cancer over the short term. 
Management of RRSO 
10. Although combined hysterectomy is not considered necessary in 
association with RRSO, it has advantages when hormone therapy for breast 
cancer or hormone replacement therapy for ovarian deficiency symptoms is 
carried out. For this reason, the advantages and disadvantages of combined 
hysterectomy associated with RRSO should be fully explained prior to surgery. 
11. Discovery of occult cancer when RRSO is carried out has been reported. 
The development of tumors in the neighborhood of the fimbria of the fallopian 
tubes has attracted attention in ovarian cancer, so that completely sectioned 
specimens of biopsy samples must be prepared. It is therefore essential to 
create a system of cooperation with the diagnostic pathology department. 
12. It must be explained that even after RRSO, there is still a 2–5% probability 
of peritoneal cancer. 
13. RRSO is recommended as primary prevention for ovarian cancer in the 
various guidelines. At the same time, there is no reliable method of ovarian 
cancer screening for women with a BRCA1/2 gene mutation who have opted 
not to have RRSO. Transvaginal ultrasound and CA125 measurement at least 
once every six months is considered to be a realistic secondary prevention 
method in actual clinical settings. However, this must be carried out with the 
understanding that, even though the previous examination gave a negative 
result, there is still a risk of so-called interval cancer, which means that 
subjective symptoms may appear and cancer may be discovered before the 
time of the next examination. 
14. Regardless of whether RRSO is carried out, the risk of breast cancer, 
pancreatic cancer, or prostate cancer is increased in individuals with BRCA1/2 
 gene mutation. Surveillance in cooperation with the relevant departments is 
therefore needed even after RRSO is carried out. 
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Hereditary breast and ovarian cancer syndrome (HBOC) is a hereditary tumor 
that can be definitively diagnosed by detection of germline mutation of the 
BRCA1 or BRCA2 gene.  
The directors of medical specialty teaching facilities were notified of the 
questionnaire by post, with the request for one respondent per facility. The 
response period was from 8 July 2014 to 31 March 2015. 
A total of 341 facilities (50.3%) responded of the 678 that were requested to 
compete the questionnaire. The responses are shown in the respective tables. 
For questions with free responses, similar answers have been grouped together, 
and the written answers have been freely translated. 
Based on these results the Japan Society of Obstetrics and Gynecology 
considers that the 14 conditions including the consulting by the specialist staff 
must be met before risk-reducing salpingo-oophorectomy is carried out. 
 



























































































































































































































































































































































































































































































































































● 2 hour session: ¥3,000–5,000  ● 30 min: ¥3,150  ● 1 hour session: ¥10,000  ● 1 hour session: 
¥3,000  ● 1 session: ¥5,000  ● 1.5 hours: ¥10,000  ● 1 hour session: ¥10,800  ● 1 session: ¥3,150  ●
¥3,000  ● ¥8,000 ● 30 min: ¥5,000 + consumption tax, initial visit fee is separate  ● 1 session, up to 
1.5 hours: ¥9,000  ● 1.5 hour session: ¥11,200  ● 30 min session: ¥5,000  ● 1 hour: ¥5,000  ● 90 
min: ¥3,150
● Initial visit: ¥10,000 + consumption tax, subsequent visit: ¥5,000 + consumption tax ● Initial visit: 
¥5,000, subsequent visit: ¥3,000  ● Initial visit: ¥10,000, subsequent visit:  ¥5,000  ● Initial visit: 
¥8,400, subsequent visit:  ¥6,300  ●Initial visit: ¥10,000, subsequent visit:  ¥5,000  ● Initial visit: 



























































































































































































































































































































































● Consideration given to age  ● Age under 44  ● If age 45 or less, carried out until age 50  ● Until age 50  ● Until 
menopause  ● Short term, until menopause


























































































































































0    1     2    3     4     5     6   12  13  1    2     3     4     5    6    7    15 1    2     3     4     5    9   11   1    2     3      1    2     3     1    2     3     1 19   
















4 2 1 1 2 1 1
23
0
10
20
30
40
50
60
70
Question 45. Number of facilities that responded: 137
Please answer to the best of your knowledge.
This question is for facilities that answered in Question 9 that there are 1 or more geneticists certified by 
the Japan Society of Human Genetics or the Japanese Society for Genetic Counseling.  Check the 
department of the primary specialty of this/these clinical geneticist(s), and write how many clinical 
geneticists there are in this department. 
